Shares of Vernalis plc (NASDAQ:VNLPY) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Zacks has also assigned Vernalis plc an industry rank of 99 out of 265 based on the ratings given to its competitors.

Separately, Stifel Nicolaus restated a “buy” rating on shares of Vernalis plc in a research note on Saturday, June 25th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Vernalis plc (NASDAQ:VNLPY) remained flat at $1.09 during trading on Wednesday. The stock’s market cap is $286.78 million. Vernalis plc has a 12 month low of $1.09 and a 12 month high of $2.43. The stock’s 50 day moving average is $1.09 and its 200 day moving average is $1.24.

About Vernalis plc

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.

5 Day Chart for NASDAQ:VNLPY

Get a free copy of the Zacks research report on Vernalis plc (VNLPY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.